Solid Biosciences to Present at Upcoming Scientific and Patient Advocacy Conferences
June 23, 2022 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Quality
June 02, 2022 08:30 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences to Participate at the Jefferies Healthcare Conference
June 02, 2022 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences to Present at ASGCT 25th Annual Meeting and CureDuchenne 2022 FUTURES National Conference
May 17, 2022 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy
April 27, 2022 07:30 ET
|
Solid Biosciences Inc.
- IGNITE DMD functional and durability patient data support advancement of SGT-001; Program transitioning to a commercially scaled transient transfection-based manufacturing process - - Novel capsid...
Solid Biosciences Management to Host Call on April 27, 2022 to Discuss Updated Corporate Strategy and First Quarter 2022 Financial Results
April 25, 2022 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and 2-Year Efficacy and Safety Data from the Ongoing Phase I/II IGNITE DMD Clinical Trial of SGT-001
March 14, 2022 08:09 ET
|
Solid Biosciences Inc.
- 2-year data from first three patients in the high dose (2E14 vg/kg) cohort suggest sustained or improved motor function, pulmonary function and clinically validated patient-reported outcomes...
Solid Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
February 10, 2022 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates
January 10, 2022 08:00 ET
|
Solid Biosciences Inc.
- Continue to advance SGT-001 by dosing additional patients in IGNITE DMD - - Advance next-generation Duchenne gene therapy program (SGT-003) to IND submission; SGT-003 has demonstrated enhanced...
Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
January 06, 2022 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...